| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 43 | 2024 | 383 | 8.150 |
Why?
|
| Cystectomy | 17 | 2024 | 102 | 2.470 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2022 | 164 | 2.380 |
Why?
|
| Phototherapy | 2 | 2019 | 35 | 1.290 |
Why?
|
| Prostate | 5 | 2024 | 378 | 1.200 |
Why?
|
| ErbB Receptors | 3 | 2019 | 485 | 1.050 |
Why?
|
| Robotics | 7 | 2013 | 267 | 1.020 |
Why?
|
| Prostatic Neoplasms | 7 | 2019 | 1721 | 0.960 |
Why?
|
| Lymph Node Excision | 6 | 2017 | 213 | 0.960 |
Why?
|
| Organ Transplantation | 3 | 2020 | 265 | 0.880 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 2358 | 0.840 |
Why?
|
| Prostatectomy | 6 | 2013 | 471 | 0.830 |
Why?
|
| Urinary Diversion | 2 | 2018 | 42 | 0.750 |
Why?
|
| Urothelium | 3 | 2022 | 70 | 0.700 |
Why?
|
| Immunotherapy | 3 | 2020 | 629 | 0.660 |
Why?
|
| Ureteroscopy | 1 | 2018 | 37 | 0.650 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2017 | 11 | 0.630 |
Why?
|
| Ureteral Obstruction | 1 | 2018 | 67 | 0.610 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 223 | 0.610 |
Why?
|
| Carcinoma | 3 | 2015 | 436 | 0.610 |
Why?
|
| Paraganglioma | 1 | 2017 | 16 | 0.600 |
Why?
|
| Biomedical Research | 1 | 2021 | 375 | 0.590 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 46 | 0.590 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 267 | 0.590 |
Why?
|
| BCG Vaccine | 2 | 2018 | 31 | 0.570 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2013 | 99 | 0.560 |
Why?
|
| Cell Proliferation | 3 | 2017 | 1578 | 0.560 |
Why?
|
| Metastasectomy | 1 | 2015 | 9 | 0.540 |
Why?
|
| Radiotherapy | 1 | 2017 | 328 | 0.540 |
Why?
|
| Lymph Nodes | 3 | 2020 | 530 | 0.540 |
Why?
|
| Proteomics | 1 | 2017 | 212 | 0.530 |
Why?
|
| Humans | 56 | 2024 | 86617 | 0.520 |
Why?
|
| Postoperative Complications | 7 | 2022 | 2207 | 0.520 |
Why?
|
| Histones | 1 | 2017 | 311 | 0.510 |
Why?
|
| Pyrimidines | 1 | 2017 | 370 | 0.510 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1169 | 0.510 |
Why?
|
| Neoplasm Invasiveness | 9 | 2024 | 552 | 0.500 |
Why?
|
| Urogenital Neoplasms | 3 | 2020 | 23 | 0.490 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 2426 | 0.490 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 3357 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2020 | 1313 | 0.450 |
Why?
|
| Lymphatic Metastasis | 6 | 2020 | 481 | 0.440 |
Why?
|
| Expert Testimony | 3 | 2020 | 46 | 0.430 |
Why?
|
| Aged | 22 | 2024 | 18402 | 0.430 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2019 | 458 | 0.430 |
Why?
|
| Urinary Bladder | 4 | 2024 | 246 | 0.420 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 141 | 0.390 |
Why?
|
| Middle Aged | 23 | 2021 | 25017 | 0.380 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 53 | 0.370 |
Why?
|
| Administration, Intravesical | 4 | 2018 | 33 | 0.360 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1464 | 0.350 |
Why?
|
| Male | 28 | 2024 | 40958 | 0.340 |
Why?
|
| Infrared Rays | 2 | 2019 | 17 | 0.330 |
Why?
|
| Neoplasm Staging | 7 | 2018 | 1937 | 0.320 |
Why?
|
| Photosensitizing Agents | 2 | 2019 | 48 | 0.320 |
Why?
|
| Time Factors | 6 | 2021 | 5209 | 0.310 |
Why?
|
| Erectile Dysfunction | 2 | 2024 | 74 | 0.310 |
Why?
|
| Mice, Nude | 3 | 2019 | 790 | 0.300 |
Why?
|
| Drugs, Investigational | 1 | 2007 | 37 | 0.300 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 353 | 0.300 |
Why?
|
| SEER Program | 2 | 2017 | 184 | 0.290 |
Why?
|
| Medical Oncology | 3 | 2020 | 359 | 0.290 |
Why?
|
| Population Surveillance | 1 | 2007 | 219 | 0.280 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 621 | 0.280 |
Why?
|
| Urologic Neoplasms | 2 | 2020 | 77 | 0.270 |
Why?
|
| Prognosis | 8 | 2020 | 3675 | 0.270 |
Why?
|
| Succinate Dehydrogenase | 2 | 2015 | 17 | 0.270 |
Why?
|
| Paraganglioma, Extra-Adrenal | 2 | 2015 | 12 | 0.270 |
Why?
|
| Neoplasms | 1 | 2020 | 2898 | 0.270 |
Why?
|
| Female | 21 | 2022 | 44509 | 0.270 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 153 | 0.260 |
Why?
|
| Consensus | 3 | 2020 | 335 | 0.250 |
Why?
|
| Biopsy | 4 | 2014 | 1162 | 0.250 |
Why?
|
| Germ-Line Mutation | 3 | 2015 | 329 | 0.240 |
Why?
|
| Anilides | 2 | 2020 | 47 | 0.230 |
Why?
|
| Prospective Studies | 5 | 2024 | 4212 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 1376 | 0.220 |
Why?
|
| Retrospective Studies | 12 | 2024 | 8477 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2024 | 7990 | 0.210 |
Why?
|
| Health Care Sector | 1 | 2021 | 13 | 0.210 |
Why?
|
| Cystoscopy | 2 | 2018 | 35 | 0.210 |
Why?
|
| Equipment and Supplies | 1 | 2021 | 30 | 0.200 |
Why?
|
| Autocrine Communication | 1 | 2021 | 18 | 0.200 |
Why?
|
| Pyridines | 2 | 2020 | 310 | 0.200 |
Why?
|
| Conflict of Interest | 1 | 2021 | 67 | 0.200 |
Why?
|
| Publishing | 1 | 2021 | 90 | 0.190 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 196 | 0.190 |
Why?
|
| History, 21st Century | 1 | 2021 | 175 | 0.190 |
Why?
|
| Forecasting | 1 | 2021 | 304 | 0.180 |
Why?
|
| United States | 9 | 2022 | 6665 | 0.180 |
Why?
|
| History, 20th Century | 1 | 2021 | 312 | 0.180 |
Why?
|
| Ferrosoferric Oxide | 1 | 2019 | 18 | 0.180 |
Why?
|
| Lymphography | 1 | 2019 | 27 | 0.180 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2019 | 17 | 0.180 |
Why?
|
| Survival Rate | 3 | 2020 | 1860 | 0.170 |
Why?
|
| Animals | 7 | 2021 | 26582 | 0.170 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 6501 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2019 | 68 | 0.170 |
Why?
|
| Urology | 2 | 2017 | 110 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1197 | 0.160 |
Why?
|
| Adult | 13 | 2020 | 25640 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 41 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 123 | 0.160 |
Why?
|
| Awareness | 1 | 2018 | 93 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2018 | 95 | 0.160 |
Why?
|
| Physicians | 2 | 2017 | 673 | 0.160 |
Why?
|
| Cancer Vaccines | 1 | 2019 | 156 | 0.160 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 170 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2020 | 199 | 0.150 |
Why?
|
| Databases, Factual | 3 | 2021 | 812 | 0.150 |
Why?
|
| Resorcinols | 1 | 2017 | 5 | 0.150 |
Why?
|
| Risk Factors | 5 | 2015 | 5417 | 0.150 |
Why?
|
| Isoindoles | 1 | 2017 | 14 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2015 | 2261 | 0.150 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 16 | 0.150 |
Why?
|
| Benzodioxoles | 1 | 2017 | 16 | 0.150 |
Why?
|
| Epigenomics | 1 | 2018 | 100 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 526 | 0.150 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 325 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2020 | 329 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 426 | 0.150 |
Why?
|
| Isoxazoles | 1 | 2017 | 77 | 0.150 |
Why?
|
| Statistics as Topic | 1 | 2017 | 238 | 0.150 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 114 | 0.140 |
Why?
|
| Mice | 4 | 2021 | 11352 | 0.140 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 72 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 185 | 0.140 |
Why?
|
| Demography | 1 | 2017 | 177 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 1538 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2017 | 106 | 0.140 |
Why?
|
| Triazoles | 1 | 2017 | 96 | 0.140 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 311 | 0.140 |
Why?
|
| Intraoperative Care | 1 | 2017 | 82 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 84 | 0.140 |
Why?
|
| Melanoma | 1 | 2020 | 454 | 0.140 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 92 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2017 | 295 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 162 | 0.140 |
Why?
|
| Benzamides | 1 | 2017 | 229 | 0.140 |
Why?
|
| Cell Division | 1 | 2017 | 696 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1685 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2017 | 504 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 178 | 0.130 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 357 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 296 | 0.130 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 15 | 0.130 |
Why?
|
| Hospitals, High-Volume | 2 | 2013 | 35 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 329 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 317 | 0.130 |
Why?
|
| Muir-Torre Syndrome | 1 | 2014 | 4 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2014 | 468 | 0.130 |
Why?
|
| Disease Progression | 2 | 2018 | 1531 | 0.130 |
Why?
|
| Facial Neoplasms | 1 | 2014 | 25 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 371 | 0.130 |
Why?
|
| Cell Survival | 1 | 2017 | 969 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 860 | 0.120 |
Why?
|
| Ureteral Neoplasms | 1 | 2014 | 13 | 0.120 |
Why?
|
| Muscles | 1 | 2014 | 194 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 311 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 999 | 0.120 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1753 | 0.120 |
Why?
|
| Logistic Models | 3 | 2013 | 1185 | 0.120 |
Why?
|
| Hospitals | 2 | 2013 | 294 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2018 | 628 | 0.110 |
Why?
|
| Hospital Administration | 1 | 2013 | 26 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 1208 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1961 | 0.110 |
Why?
|
| Signal Transduction | 2 | 2017 | 3241 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1384 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 589 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 266 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 267 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2012 | 176 | 0.100 |
Why?
|
| Length of Stay | 2 | 2013 | 700 | 0.100 |
Why?
|
| Dyslipidemias | 1 | 2012 | 109 | 0.100 |
Why?
|
| Michigan | 1 | 2011 | 52 | 0.100 |
Why?
|
| Urologic Surgical Procedures | 1 | 2012 | 146 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 2436 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 364 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 391 | 0.090 |
Why?
|
| Medicare | 3 | 2022 | 406 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 302 | 0.090 |
Why?
|
| Ilium | 1 | 2009 | 18 | 0.090 |
Why?
|
| Disclosure | 2 | 2021 | 108 | 0.080 |
Why?
|
| Hypertension | 2 | 2020 | 1141 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2705 | 0.080 |
Why?
|
| Reoperation | 1 | 2011 | 597 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 394 | 0.080 |
Why?
|
| Drainage | 1 | 2009 | 157 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 2270 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2601 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 645 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 370 | 0.080 |
Why?
|
| Drug Design | 1 | 2007 | 124 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 858 | 0.070 |
Why?
|
| Transplantation, Heterologous | 2 | 2021 | 363 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 353 | 0.060 |
Why?
|
| Incidence | 2 | 2022 | 1577 | 0.060 |
Why?
|
| Capecitabine | 1 | 2024 | 96 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2013 | 1004 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1565 | 0.060 |
Why?
|
| Europe | 2 | 2013 | 309 | 0.050 |
Why?
|
| Financial Statements | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2022 | 148 | 0.050 |
Why?
|
| Urologists | 1 | 2021 | 24 | 0.050 |
Why?
|
| Professional Misconduct | 1 | 2021 | 25 | 0.050 |
Why?
|
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 612 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2021 | 38 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 54 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 70 | 0.050 |
Why?
|
| Young Adult | 3 | 2020 | 5974 | 0.050 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2021 | 59 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2020 | 4 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1683 | 0.050 |
Why?
|
| Hepatitis | 1 | 2020 | 35 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2020 | 31 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 56 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 179 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2020 | 58 | 0.050 |
Why?
|
| Receptors, CXCR4 | 1 | 2020 | 44 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1673 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.050 |
Why?
|
| RNA Interference | 1 | 2021 | 369 | 0.050 |
Why?
|
| Fatigue | 1 | 2020 | 174 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 547 | 0.040 |
Why?
|
| Diarrhea | 1 | 2020 | 182 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 250 | 0.040 |
Why?
|
| Patient Selection | 2 | 2015 | 685 | 0.040 |
Why?
|
| Urethra | 1 | 2018 | 113 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 239 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 167 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 298 | 0.040 |
Why?
|
| Drug Industry | 1 | 2017 | 54 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 66 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 592 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 418 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 746 | 0.040 |
Why?
|
| Pelvis | 1 | 2017 | 95 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 217 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 728 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2015 | 40 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 78 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 555 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 37 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 776 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 217 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 363 | 0.030 |
Why?
|
| Checklist | 1 | 2015 | 57 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2015 | 56 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2014 | 43 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 52 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 177 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 334 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2013 | 31 | 0.030 |
Why?
|
| Child | 2 | 2015 | 6926 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2818 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 173 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2013 | 18 | 0.030 |
Why?
|
| Asia | 1 | 2013 | 95 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 8979 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 115 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 752 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2013 | 303 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2013 | 160 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 185 | 0.030 |
Why?
|
| Luminescence | 1 | 2010 | 16 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2012 | 115 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 678 | 0.020 |
Why?
|
| Necrosis | 1 | 2010 | 204 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1804 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1991 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 288 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2012 | 294 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 594 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 329 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 3967 | 0.020 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 19 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2007 | 23 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 70 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1801 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 469 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2007 | 281 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 394 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2501 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1034 | 0.020 |
Why?
|
| Hypoxia | 1 | 2010 | 641 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 1204 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2232 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 930 | 0.010 |
Why?
|